Author
Listed:
- Ariadna Cilleros-Portet
(Biobizkaia Health Research Institute and University of the Basque Country (UPV/EHU))
- Corina Lesseur
(Icahn School of Medicine at Mount Sinai)
- Sergi Marí
(Biobizkaia Health Research Institute and University of the Basque Country (UPV/EHU))
- Marta Cosin-Tomas
(ISGlobal
Instituto de Salud Carlos III
Universitat Pompeu Fabra)
- Manuel Lozano
(FISABIO-Universitat Jaume I-Universitat de València
Universitat de València)
- Amaia Irizar
(Instituto de Salud Carlos III
University of the Basque Country (UPV/EHU)
Biogipuzkoa Health Research Institute)
- Amber Burt
(Emory University)
- Iraia García-Santisteban
(Biobizkaia Health Research Institute and University of the Basque Country (UPV/EHU))
- Diego Garrido-Martín
(Universitat de Barcelona (UB))
- Geòrgia Escaramís
(Instituto de Salud Carlos III
Universitat de Barcelona)
- Alba Hernangomez-Laderas
(Biobizkaia Health Research Institute and University of the Basque Country (UPV/EHU))
- Raquel Soler-Blasco
(Instituto de Salud Carlos III
FISABIO-Universitat Jaume I-Universitat de València
Universitat de València)
- Charles E. Breeze
(University College London)
- Bárbara P. Gonzalez-Garcia
(Biobizkaia Health Research Institute and University of the Basque Country (UPV/EHU))
- Loreto Santa-Marina
(Instituto de Salud Carlos III
Biogipuzkoa Health Research Institute
Subdirectorate of Public Health of Gipuzkoa)
- Jia Chen
(Icahn School of Medicine at Mount Sinai)
- Sabrina Llop
(Instituto de Salud Carlos III
FISABIO-Universitat Jaume I-Universitat de València)
- Mariana F. Fernández
(Instituto de Salud Carlos III
University of Granada
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA))
- Martine Vrijheid
(ISGlobal
Instituto de Salud Carlos III
Universitat Pompeu Fabra)
- Jesús Ibarluzea
(Instituto de Salud Carlos III
Biogipuzkoa Health Research Institute
Subdirectorate of Public Health of Gipuzkoa)
- Mònica Guxens
(ISGlobal
Instituto de Salud Carlos III
Universitat Pompeu Fabra
University Medical Centre)
- Carmen Marsit
(Emory University)
- Mariona Bustamante
(ISGlobal
Instituto de Salud Carlos III
Universitat Pompeu Fabra)
- Jose Ramon Bilbao
(Biobizkaia Health Research Institute and University of the Basque Country (UPV/EHU)
CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM))
- Nora Fernandez-Jimenez
(Biobizkaia Health Research Institute and University of the Basque Country (UPV/EHU))
Abstract
Increasing evidence supports the role of the placenta in neurodevelopment and in the onset of neuropsychiatric disorders. Recently, mQTL and iQTL maps have proven useful in understanding relationships between SNPs and GWAS that are not captured by eQTL. In this context, we propose that part of the genetic predisposition to complex neuropsychiatric disorders acts through placental DNA methylation. We construct a public placental cis-mQTL database including 214,830 CpG sites calculated in 368 fetal placenta DNA samples from the INMA project, and run cell type-, gestational age- and sex-imQTL models. We combine these data with summary statistics of GWAS on ten neuropsychiatric disorders using summary-based Mendelian randomization and colocalization. We also evaluate the influence of identified DNA methylation sites on placental gene expression in the RICHS cohort. We find that placental cis-mQTLs are enriched in placenta-specific active chromatin regions, and establish that part of the genetic burden for schizophrenia, bipolar disorder, and major depressive disorder confers risk through placental DNA methylation. The potential causality of several of the observed associations is reinforced by secondary association signals identified in conditional analyses, the involvement of cell type-imQTLs, and the correlation of identified DNA methylation sites with the expression levels of relevant genes in the placenta.
Suggested Citation
Ariadna Cilleros-Portet & Corina Lesseur & Sergi Marí & Marta Cosin-Tomas & Manuel Lozano & Amaia Irizar & Amber Burt & Iraia García-Santisteban & Diego Garrido-Martín & Geòrgia Escaramís & Alba Herna, 2025.
"Potentially causal associations between placental DNA methylation and schizophrenia and other neuropsychiatric disorders,"
Nature Communications, Nature, vol. 16(1), pages 1-21, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57760-3
DOI: 10.1038/s41467-025-57760-3
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57760-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.